A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions

Health Volunteer

Interventions

DRUG

RBD5044

Subcutaneously Administered RBD5044 in Healthy Subjects

DRUG

Placebo

Subcutaneously Administered Placebo in Healthy Subjects

Trial Locations (1)

Q-Pharm Pty Limited, Brisbane

All Listed Sponsors

lead

Suzhou Ribo Life Science Co. Ltd.

INDUSTRY